Line 1: |
Line 1: |
| Welcome! | | Welcome! |
| | | |
− | *For assignments, please see the "Author" column below (3rd column from left). If no name is present, volunteer to create content! | + | '''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' |
| + | |
| + | *For assignments, please see the "Author" column below (highlighted blue). |
| + | |
| + | *If empty (no name is present), please volunteer to create content for that disease! |
| + | *If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content. |
| + | |
| *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | | *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. |
− | *Note - NEW (No Prior) means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added. | + | *Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. |
| | | |
| <br /> | | <br /> |
| {| class="wikitable" style="margin:auto" | | {| class="wikitable" style="margin:auto" |
− | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content</big> | + | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> |
| |- | | |- |
− | !Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition) | + | !Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) |
| + | !Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition) |
| !Correlated Prior Disease Name (4th Edition) | | !Correlated Prior Disease Name (4th Edition) |
| !Correlated Prior Author (4th Edition) | | !Correlated Prior Author (4th Edition) |
Line 22: |
Line 29: |
| ----<br /> | | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
− | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| || | + | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra |
| + | |4/8/24 |
| + | | ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 48: |
Line 69: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| || |
| |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive |
| |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |
Line 55: |
Line 76: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Chronic Neutrophilic Leukemia (CNL) | | |Chronic Neutrophilic Leukemia (CNL) |
| |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally |
Line 62: |
Line 84: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Chronic Eosinophilic Leukemia, Not Otherwise Specified | | |Chronic Eosinophilic Leukemia, Not Otherwise Specified |
| |Chelsea D. Kramish; Daynna J.Wolff | | |Chelsea D. Kramish; Daynna J.Wolff |
Line 69: |
Line 92: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Polycythemia Vera (PV) | | |Polycythemia Vera (PV) |
| |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |
Line 76: |
Line 100: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Essential Thrombocythemia (ET) | | |Essential Thrombocythemia (ET) |
| |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN |
Line 83: |
Line 108: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Primary Myelofibrosis (PMF) | | |Primary Myelofibrosis (PMF) |
| |T. Niroshi Senaratne, UCLA | | |T. Niroshi Senaratne, UCLA |
Line 90: |
Line 116: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| || | + | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING |
| + | | || || || ||FQR|| || |
| |Juvenile Myelomonocytic Leukemia (JMML) | | |Juvenile Myelomonocytic Leukemia (JMML) |
| |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | | |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> |
Line 101: |
Line 128: |
| |FQR has emailed SR several times, last 4/20/22 | | |FQR has emailed SR several times, last 4/20/22 |
| |- | | |- |
− | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Myeloproliferative Neoplasm (MPN), Unclassifiable | | |Myeloproliferative Neoplasm (MPN), Unclassifiable |
| |Thomas Lee, MD, PhD, University of California, Los Angeles | | |Thomas Lee, MD, PhD, University of California, Los Angeles |
Line 108: |
Line 136: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Cutaneous Mastocytosis | | |Cutaneous Mastocytosis |
| |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | | |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD |
Line 115: |
Line 144: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || |
| |Systemic Mastocytosis | | |Systemic Mastocytosis |
− | |'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University | + | |Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Mast Cell Sarcoma | | |Mast Cell Sarcoma |
| |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | | |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL |
Line 129: |
Line 159: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Myelodysplastic Syndrome (MDS) with Isolated del(5q) | | |Myelodysplastic Syndrome (MDS) with Isolated del(5q) |
| |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | | |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG |
Line 136: |
Line 167: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 164: |
Line 196: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Myelodysplastic Syndrome (MDS) with Excess Blasts | | |Myelodysplastic Syndrome (MDS) with Excess Blasts |
| |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center |
Line 171: |
Line 204: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Refractory Cytopenia of Childhood | | |Refractory Cytopenia of Childhood |
| |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center |
Line 178: |
Line 212: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Refractory Cytopenia of Childhood | | |Refractory Cytopenia of Childhood |
| |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center |
Line 185: |
Line 220: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Chronic Myelomonocytic Leukemia (CMML) | | |Chronic Myelomonocytic Leukemia (CMML) |
| |Linsheng Zhang, MD, PhD | | |Linsheng Zhang, MD, PhD |
Line 192: |
Line 228: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | | |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative |
| |Linsheng Zhang, MD, PhD | | |Linsheng Zhang, MD, PhD |
Line 199: |
Line 236: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | | |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) |
| |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | | |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine |
Line 206: |
Line 244: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING |
| + | | || || || ||FQR|| || |
| |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable |
| |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | | |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia |
Line 215: |
Line 254: |
| |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 231: |
Line 270: |
| |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 247: |
Line 286: |
| |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 263: |
Line 302: |
| |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 279: |
Line 318: |
| |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | | |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 295: |
Line 334: |
| |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 311: |
Line 350: |
| |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 327: |
Line 366: |
| |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 359: |
Line 398: |
| |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 375: |
Line 414: |
| |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 391: |
Line 430: |
| |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 423: |
Line 462: |
| |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 439: |
Line 478: |
| |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 455: |
Line 494: |
| |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 471: |
Line 510: |
| |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 487: |
Line 526: |
| |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 503: |
Line 542: |
| |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 519: |
Line 558: |
| |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 535: |
Line 574: |
| |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 551: |
Line 590: |
| |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 586: |
Line 625: |
| |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 602: |
Line 641: |
| |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 618: |
Line 657: |
| |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 634: |
Line 673: |
| |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 650: |
Line 689: |
| |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 666: |
Line 705: |
| |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 749: |
Line 788: |
| |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] |
| |Disease | | |Disease |
| + | |Tracy Tucker, PhD, FCCMG |
| + | |4/6/24 |
| | | | | |
− | | | + | |Pending |
− | |
| |
− | |
| |
| | | | | |
| |JH_MS | | |JH_MS |
Line 765: |
Line 804: |
| |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] |
| |Disease | | |Disease |
| + | |Tracy Tucker, PhD, FCCMG |
| + | |4/6/24 |
| | | | | |
− | | | + | |Pending |
− | |
| |
− | |
| |
| | | | | |
| |JH_MS | | |JH_MS |
Line 797: |
Line 836: |
| |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 813: |
Line 852: |
| |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 829: |
Line 868: |
| |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 861: |
Line 900: |
| |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 881: |
Line 920: |
| ----<br /> | | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
| |[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]] | | |[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]] |
Line 911: |
Line 962: |
| |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 927: |
Line 978: |
| |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 943: |
Line 994: |
| |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,055: |
Line 1,106: |
| |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,075: |
Line 1,126: |
| ----<br /> | | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| ----<br /> | | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
| |[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | | |[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] |
Line 1,154: |
Line 1,216: |
| |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,170: |
Line 1,232: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,186: |
Line 1,248: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,202: |
Line 1,264: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,218: |
Line 1,280: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] |
| |Disease | | |Disease |
− | |Holli authoring - Complete? Looks like needs more editing of tables | + | |Holli Drendel |
− | |
| |
| | | | | |
| | | | | |
| + | |?Complete? Looks like tables need more editing. |
| | | | | |
| |HD | | |HD |
Line 1,234: |
Line 1,296: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,250: |
Line 1,312: |
| |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,266: |
Line 1,328: |
| |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,282: |
Line 1,344: |
| |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,314: |
Line 1,376: |
| |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,330: |
Line 1,392: |
| |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,411: |
Line 1,473: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| || || || || ||Shivani Golem (SG) | + | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty |
| + | | || || || ||Shivani Golem (SG) |
| | || | | | || |
| |Monoclonal B-cell Lymphocytosis | | |Monoclonal B-cell Lymphocytosis |
| |Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | | |Tsigab Bahta Hagos (trainee) / Shashirekha Shetty |
− | |PENDING | + | |PENDING, 4/30/2024 |
| | | | | |
| |Assigned 12/19/2022 with completion date of 1/19/2023 | | |Assigned 12/19/2022 with completion date of 1/19/2023 |
Line 1,424: |
Line 1,487: |
| | | |
| Honey Reddi, PhD, Belay Diagnostics | | Honey Reddi, PhD, Belay Diagnostics |
− | | || ||Complete (Shivani, please confirm)|| ||SG|| || | + | | || ||Complete|| ||SG|| || |
| |Already converted to 5th edition | | |Already converted to 5th edition |
| |Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | | |Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD |
Line 1,431: |
Line 1,494: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| || || || || ||SG|| || | + | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| |
| + | | || || || ||SG|| || |
| |Hairy Cell Leukemia | | |Hairy Cell Leukemia |
| |Snehal Patel, MD, PhD | | |Snehal Patel, MD, PhD |
Line 1,438: |
Line 1,502: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| || || || || ||SG|| || | + | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| |
| + | | || || || ||SG|| || |
| |Splenic Marginal Zone Lymphoma | | |Splenic Marginal Zone Lymphoma |
| |Snehal Patel, MD, PhD | | |Snehal Patel, MD, PhD |
Line 1,445: |
Line 1,510: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| || || || || ||SG|| || | + | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| |
| + | | || || || ||SG|| || |
| |Splenic Diffuse Red Pulp Small B-cell Lymphoma | | |Splenic Diffuse Red Pulp Small B-cell Lymphoma |
| |Snehal Patel, MD, PhD | | |Snehal Patel, MD, PhD |
Line 1,470: |
Line 1,536: |
| |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,486: |
Line 1,552: |
| |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,520: |
Line 1,586: |
| |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,536: |
Line 1,602: |
| |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,584: |
Line 1,650: |
| |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,616: |
Line 1,682: |
| |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,632: |
Line 1,698: |
| |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,648: |
Line 1,714: |
| |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | | |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] |
| |Disease | | |Disease |
− | | | + | |PENDING |
| | | | | |
| | | | | |
Line 1,657: |
Line 1,723: |
| | | | | |
| |Mantle Cell Lymphoma | | |Mantle Cell Lymphoma |
− | |* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | + | |Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas |
| |Pending | | |Pending |
| | | | | |
Line 1,694: |
Line 1,760: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified |
| |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center |
Line 1,708: |
Line 1,775: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements |
| |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland |
Line 1,715: |
Line 1,783: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |ALK-Positive Large B-cell Lymphoma | | |ALK-Positive Large B-cell Lymphoma |
| |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) |
Line 1,722: |
Line 1,791: |
| |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 |
| |- | | |- |
− | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Large B-cell Lymphoma with IRF4 Rearrangement | | |Large B-cell Lymphoma with IRF4 Rearrangement |
| |Afia Hasnain, MBBS, PhD | | |Afia Hasnain, MBBS, PhD |
Line 1,729: |
Line 1,799: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Burkitt-Like Lymphoma with 11q Aberration | | |Burkitt-Like Lymphoma with 11q Aberration |
| |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina |
Line 1,743: |
Line 1,814: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor |
| + | |3/22/24|| ||Pending|| ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,757: |
Line 1,829: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | + | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING |
| + | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam |
| |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,771: |
Line 1,844: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Plasmablastic Lymphoma | | |Plasmablastic Lymphoma |
| |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |
Line 1,778: |
Line 1,852: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS |
| |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital |
Line 1,792: |
Line 1,867: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Intravascular Large B-cell Lymphoma | | |Intravascular Large B-cell Lymphoma |
| |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy |
Line 1,813: |
Line 1,889: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| || | + | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) |
| |Aiko Otsubo, PhD, Indiana University, Holli Drendel | | |Aiko Otsubo, PhD, Indiana University, Holli Drendel |
Line 1,820: |
Line 1,897: |
| | | | | |
| |- | | |- |
− | |Burkitt lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING |
| + | | || || || ||GC|| || |
| |Burkitt Lymphoma | | |Burkitt Lymphoma |
| |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland |
Line 1,827: |
Line 1,905: |
| | | | | |
| |- | | |- |
− | |Primary effusion lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,834: |
Line 1,912: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,841: |
Line 1,919: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | + | |[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,848: |
Line 1,926: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| || | + | |[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,855: |
Line 1,933: |
| | | | | |
| |- | | |- |
− | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. | + | |[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. |
| Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | | Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" |
| | || || || ||GC|| || | | | || || || ||GC|| || |
Line 1,864: |
Line 1,942: |
| | | | | |
| |- | | |- |
− | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | + | |[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,871: |
Line 1,949: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || | + | |[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,878: |
Line 1,956: |
| | | | | |
| |- | | |- |
− | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| || | + | |[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,885: |
Line 1,963: |
| | | | | |
| |- | | |- |
− | |Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | + | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING |
− | |GC|| ||
| + | | || || || |
| + | |GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma |
| |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma |
| |(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | | |(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez |
Line 1,893: |
Line 1,972: |
| | | | | |
| |- | | |- |
− | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,900: |
Line 1,979: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Cold agglutinin disease | + | |[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] |
| |Disease | | |Disease |
| | | | | |
Line 1,916: |
Line 1,995: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | + | |[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,923: |
Line 2,002: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | + | |[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,930: |
Line 2,009: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | + | |[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG |
| | || | | | || |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,938: |
Line 2,017: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG | + | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING |
| + | | || || || ||SG |
| | || | | | || |
| |Primary Amyloidosis | | |Primary Amyloidosis |
Line 1,946: |
Line 2,026: |
| | | | | |
| |- | | |- |
− | |Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG | + | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING |
| + | | || || || ||SG |
| | || | | | || |
| |Light Chain and Heavy Chain Deposition Disease | | |Light Chain and Heavy Chain Deposition Disease |
Line 1,954: |
Line 2,035: |
| | | | | |
| |- | | |- |
− | |Mu heavy chain disease||Disease|| || || || || ||SG | + | |[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG |
| | || | | | || |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,962: |
Line 2,043: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Gamma heavy chain disease||Disease|| || || || || ||SG | + | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING |
| + | | || || || ||SG |
| | || | | | || |
| |Gamma Heavy Chain Disease | | |Gamma Heavy Chain Disease |
Line 1,970: |
Line 2,052: |
| | | | | |
| |- | | |- |
− | |Alpha heavy chain disease||Disease|| || || || || ||SG | + | |[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG |
| | || | | | || |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,978: |
Line 2,060: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Plasmacytoma||Disease|| || || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | + | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING |
| + | | || || || |
| |SG | | |SG |
− | | || | + | | ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) |
| |NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | | |NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 1,987: |
Line 2,070: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG | + | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING |
− | | ||
| + | | || || || ||SG |
| + | | ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page |
| |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants |
| |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | | |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG |
Line 1,995: |
Line 2,079: |
| | | | | |
| |- | | |- |
− | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | + | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING |
| + | | || || || |
| |SG | | |SG |
− | | || | + | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content |
| |(1) POEMS Syndrome + (2) TEMPI Syndrome | | |(1) POEMS Syndrome + (2) TEMPI Syndrome |
| |(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | | |(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD |
Line 2,003: |
Line 2,088: |
| | | | | |
| | | | | |
| + | |- |
| + | |Disease (5th Edition) |
| + | |Page Type |
| + | |Author (5th Edition) (Note: please indicate trainees in parenthesis) |
| + | |Date Assigned to Author (5th Edition) |
| + | |Target Completion Date (5th Edition) |
| + | |Content Status (5th Edition) (Pending or Complete) |
| + | |Date Completed by Author (5th Edition) |
| + | |Associate Editor |
| + | |Date of Last Editor Review (5th Edition) |
| + | |Notes (5th Edition) |
| + | |Correlated Prior Disease Name (4th Edition) |
| + | |Correlated Prior Author (4th Edition) |
| + | |Prior Content Status (4th Edition) (Pending or Complete) |
| + | |Prior Date of Last Editor Review (4th Edition) |
| + | |Prior Notes (4th Edition) |
| |- | | |- |
| |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | | |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
Line 2,010: |
Line 2,111: |
| ----<br /> | | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
− | |Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | + | |[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK) |
| | || | | | || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
− | |Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD |
− | | | + | |3/25/2024 |
− | | | + | | || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
− | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| || | + | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
− | |Early T-precursor lymphoblastic leukaemia / lymphoma | + | |[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] |
| |Disease | | |Disease |
| + | |Fei Yang, MD |
| | | | | |
| | | | | |
| + | |Pending |
| | | | | |
| + | |SK |
| | | | | |
| | | | | |
− | |HD | + | |Early T-Cell Precursor Lymphoblastic Leukemia |
− | |
| |
− | |
| |
− | |
| |
| |Fei Yang, MD, FACMG, Kaiser Permanente Northwest | | |Fei Yang, MD, FACMG, Kaiser Permanente Northwest |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |T-prolymphocytic leukaemia | + | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] |
| |Disease | | |Disease |
| + | |Parastou Tizro, MD (trainee); |
| + | Sumire Kitahara, MD |
| + | |3/17/2024 |
| | | | | |
| + | |Pending |
| | | | | |
| + | |SK |
| | | | | |
| | | | | |
− | | | + | |NEW (No Prior) |
− | |SK | + | |NEW (No Prior) |
− | |
| + | |NEW (No Prior) |
− | |
| + | |NEW (No Prior) |
− | |
| + | |NEW (No Prior) |
− | |
| |
− | | | |
− | | | |
− | | | |
| |- | | |- |
− | |T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| || | + | |[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS |
− | | | + | |3/17/2024 |
− | |*Michelle Don, MD, MS | + | |6/30/24 |
− | | | + | |Pending |
| + | | ||SK|| || |
| + | |T-cell Large Granular Lymphocytic Leukemia |
| + | |Michelle Don, MD, MS |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| || | + | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); |
− | | | + | Michelle Don, MD, MS |
| + | |3/17/2024 |
| + | |6/30/24 |
| + | |Pending |
| + | | ||SK|| || |
| + | |Chronic Lymphoproliferative Disorder of NK Cells |
| |Michelle Don, MD | | |Michelle Don, MD |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| |
− | | | + | | || || || ||SK|| || |
| + | |Adult T-cell Leukemia/Lymphoma |
| |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center |
− | | | + | |?Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Sezary syndrome||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD |
− | | | + | |3/22/2024 |
| + | | || || ||SK|| || |
| + | |Sézary Syndrome |
| |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING |
− | | | + | | || || || ||SK|| || |
| + | |Aggressive NK-cell Leukemia |
| |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD |
− | | | + | |?Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc |
− | | | + | |3/19/2024 |
− | | | + | | ||Pending |
− | | | + | | ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee), |
− | | | + | |
− | | | + | Andrew Siref, MD |
− | | | + | |4/12/2024 |
− | | | + | | ||Pending |
− | | | + | | ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Mycosis fungoides||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD |
− | | | + | |3/22/2024 |
| + | | || || ||SK|| || |
| + | |Mycosis Fungoides |
| |Jane Scribner, MD and Daynna J. Wolff, PhD | | |Jane Scribner, MD and Daynna J. Wolff, PhD |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING |
− | | | + | | || || || ||SK|| || |
| + | |Primary Cutaneous Anaplastic Large Cell Lymphoma |
| |Theresa Spivey, MD, Shashirekha Shetty, PhD | | |Theresa Spivey, MD, Shashirekha Shetty, PhD |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) |
− | | | + | |3/19/2024 |
− | | | + | | ||Pending |
− | | | + | | ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD |
| + | | || || || ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee), |
| + | |
| + | Andrew Siref, MD |
| + | |4/12/2024|| ||Pending |
| + | | ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| |
| + | | || || || ||SK|| || |
| + | |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract |
| + | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), |
| + | Andrew Siref, MD |
| + | |3/20/2024 |
| + | | ||Pending|| ||SK|| || |
| + | |Enteropathy-Associated T-cell Lymphoma |
| + | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD |
| + | |Complete |
| + | |1/21/2021 |
| | | | | |
| |- | | |- |
− | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), |
| + | Andrew Siref, MD |
| + | |3/20/2024 |
| + | | ||Pending|| ||SK|| || |
| + | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma |
| + | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD |
| + | |Pending |
| | | | | |
| | | | | |
| + | |- |
| + | |[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease|| |
| + | | || || || ||SK|| || |
| + | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) |
| + | |Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) |
| + | |Complete |
| + | |9/26/2022 |
| | | | | |
| + | |- |
| + | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); |
| + | Michelle Don, MD, MS |
| + | |3/19/2024 |
| + | |6/30/24 |
| + | |Pending |
| + | | ||SK|| || |
| + | |Hepatosplenic T-cell Lymphoma |
| + | |Michelle Don, MD, MS |
| + | |Complete |
| + | |1/21/2021 |
| | | | | |
| + | |- |
| + | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) |
| + | |
| + | Sumire Kitahara, MD |
| + | | || ||Pending |
| + | | ||SK|| || |
| + | |Anaplastic Large Cell Lymphoma, ALK-Positive |
| + | |Miguel Gonzalez Mancera, MD |
| + | |
| + | Sumire Kitahara, MD |
| + | |
| + | Cedars-Sinai, Los Angeles, CA |
| + | |Complete |
| + | |09/23/2022 |
| | | | | |
| |- | | |- |
− | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | + | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) |
− | | | + | Sumire Kitahara, MD |
− | | | + | | || ||Pending |
| + | | ||SK|| || |
| + | |Anaplastic Large Cell Lymphoma, ALK-Negative |
| + | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA |
| + | |Complete |
| + | |09/23/2022 |
| | | | | |
| + | |- |
| + | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD |
| + | |4/1/2024 |
| + | | ||Pending|| ||SK|| || |
| + | |Breast Implant-Associated Anaplastic Large Cell Lymphoma |
| + | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 |
− | | | + | | ||Pending|| ||SK|| ||prior authors not available |
− | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | + | |Angioimmunoblastic T-cell Lymphoma |
− | | | + | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 |
− | | | + | | ||Pending|| ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| |
− | | | + | | || || || ||SK|| || |
− | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | + | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype |
− | | | + | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD |
− | | | + | |6/25/2023 |
− | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | + | | || || ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | + | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| || |
− | | | + | |NEW (No Prior) |
− | |Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc |
| + | |3/19/2024 |
| + | | ||Pending |
| + | | ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD |
| + | |3/25/2024 |
| + | | || || ||SK|| || |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD |
| + | |3/25/2024 |
| + | | || || ||SK|| ||prior authors not available |
| + | |Systemic EBV-Positive T-cell Lymphoma of Childhood |
| + | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA |
| + | |Complete |
| + | |11/21/2021 |
| | | | | |
| |- | | |- |
− | |Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| || | + | |CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
| | | | | |
− | |*Michelle Don, MD, MS
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
− | |-
| + | ----<br /> |
− | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
| |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
− | |-
| + | ----<br /> |
− | |ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | + | | |
| + | ----<br /> |
| | | | | |
− | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
− | |Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] |
| + | |Disease |
| + | |PENDING |
| | | | | |
− | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center
| |
| | | | | |
| | | | | |
| | | | | |
− | |- | + | |GC |
− | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| ||
| |
| | | | | |
− | |* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG
| |
| | | | | |
| + | |Follicular Dendritic Cell Sarcoma |
| + | |Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG |
| + | |?Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || | + | |[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]] |
| + | |Disease |
| | | | | |
| | | | | |
Line 2,257: |
Line 2,553: |
| | | | | |
| | | | | |
− | |- | + | |GC |
− | |Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
| |
− | |
| |
− | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD
| |
− | |
| |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]] |
| + | |Disease |
| | | | | |
| | | | | |
Line 2,271: |
Line 2,569: |
| | | | | |
| | | | | |
− | |- | + | |GC |
− | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
| |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]] |
| + | |Disease |
| | | | | |
| | | | | |
− | |
| |
− | |-
| |
− | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
| |
| | | | | |
| | | | | |
| | | | | |
| + | |GC |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] |
| + | |Disease |
| | | | | |
| | | | | |
Line 2,292: |
Line 2,601: |
| | | | | |
| | | | | |
− | |- | + | |GC |
− | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
| |
− | |
| |
− | |
| |
− | |
| |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Splenic hamartoma|Splenic hamartoma]] |
| + | |Disease |
| | | | | |
| | | | | |
Line 2,306: |
Line 2,617: |
| | | | | |
| | | | | |
− | |- | + | |GC |
− | |Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
| |
− | |
| |
− | |*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA
| |
− | |
| |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
− | |CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | + | |[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]] |
| + | |Disease |
| | | | | |
− | ----<br />
| |
| | | | | |
− | ----<br />
| |
| | | | | |
| | | | | |
| | | | | |
| + | |GC |
| | | | | |
| | | | | |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| + | |- |
| + | |CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
− | |-
| + | ----<br /> |
− | |Follicular dendritic cell sarcoma
| |
− | |Disease
| |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| | | | | |
− | |GC
| + | ----<br /> |
− | |
| |
− | |
| |
− | |
| |
− | |Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
| |
− | |
| |
| | | | | |
| + | ----<br /> |
| | | | | |
| + | ----<br /> |
| |- | | |- |
− | |EBV-positive inflammatory follicular dendritic cell sarcoma | + | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| || |
− | |Disease | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | |
− | |GC | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
| |- | | |- |
− | |Fibroblastic reticular cell tumour | + | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| || |
− | |Disease | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | |
− | |GC | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
| |- | | |- |
− | |Intranodal palisaded myofibroblastoma | + | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| || |
− | |Disease | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | |
− | |GC | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
| |- | | |- |
− | |Littoral cell angioma | + | |[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| || |
− | |Disease | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | |
− | |GC | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | | | |
− | |- | |
− | |Splenic hamartoma | |
− | |Disease | |
− | | | |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |GC
| |
− | |
| |
− | |
| |
− | |
| |
− | | | |
− | | | |
− | | | |
− | | | |
− | |- | |
− | |Sclerosing angiomatoid nodular transformation (SANT) of spleen
| |
− | |Disease
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |GC
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |- | |
− | |CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
| |
− | |
| |
− | ----<br />
| |
− | |
| |
− | ----<br />
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Fanconi anaemia||Disease|| || || || || ||NA|| ||
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Bloom syndrome||Disease|| || || || || ||NA|| ||
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |-
| |
− | |RASopathies||Disease|| || || || || ||NA|| ||
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
− | |
| |
| |} | | |} |